App-Quantinova.ai

SNX3 Regulates Recycling of the Transferrin Receptor and Iron Assimilation in Developing Erythrocytes*

Daniel Garcia Santos - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

N/A

High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy

Grossmann Vera - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

EZH2

Mature Results From ECOG Study E1405 A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Brad S. Kahl - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

Cyclophosphamide

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Jason Gotlib - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Essential thrombocythemia

Momelotinib

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Richard H. van der Jagt - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

Cyclophosphamide

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Beate Klimm - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

N/A

Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

Fengmin Zhao - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Rituximab

A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

Sundar Jagannath - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Myeloma

Methylprednisolone

ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL

Huimin Geng - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

L-Tyrosine

Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation

Susana Ben-Neriah - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era

Paul R. Yenson - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Rituximab

Mir-137 and Mir-197 within Chromosome 1p Minimal Deletion Region Regulate Apoptotic Activity in Multiple Myeloma by Targeting MCL 1

Venus Onay - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Role of Mir-30e in Multiple Myeloma Cells Resistance to Lenalidomide and Bortezomib

Kathy Gratton - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622

Kirk R. Schultz - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute lymphoblastic leukemia

Imatinib

Role of Gas6 in Cancer-Induced Venous Thrombosis

Catherine A Lemarie - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Hemostatic Solution

Functional Characterization of the Type 1 VWD Candidate VWF Gene Variants: P.M771I, p.L881R, p.P1413L, and p.Q1475X

Christine Brown - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Outpatient Treatment of Symptomatic Pulmonary Embolism: A Systematic Review and Meta-Analysis

Gregoire Le Gal - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Heparin

No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial

Mary Eapen - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hematological malignancies

Mycophenolate mofetil

Psi Domain of b3 Integrin Has Endogenous Thiol Isomerase Function and Is a Potential New Target for Anti-Thrombotic Therapy

Pingguo Chen - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Bacitracin

Predicting Venous Thromboembolism Recurrence Risk in Patients with Cancer: A Validation Study

Gauruv Bose - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pulmonary embolism

Warfarin

Filters

28841 Abstracts